Equity Analysis /
United States of America

US : InflaRx N.V. - IFRX | 4Q21 Update: Ruminating on Phase 3 HS Plans Since FDA Corrected It's Erroneous Advice Letter

    Contributors
    Timur Ivannikov
    Ryan Deschner
    CGS-CIMB
    26 March 2022
    Published by